Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.04)
# 2,918
Out of 4,876 analysts
171
Total ratings
37.95%
Success rate
-8.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $1.97 | +204.57% | 3 | Jun 25, 2025 | |
| EXEL Exelixis | Maintains: Market Outperform | $47 → $50 | $43.09 | +16.04% | 22 | Jun 23, 2025 | |
| ELEV Elevation Oncology | Reiterates: Market Perform | n/a | $0.39 | - | 8 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $4.81 | +211.85% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.41 | +148.96% | 13 | May 29, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $46.70 | +84.15% | 15 | May 21, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $2.65 | +126.42% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $12.35 | +61.94% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $4.88 | +84.43% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $0.89 | +574.16% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.59 | +401.39% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $4.00 | +400.00% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.31 | +1,197.71% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $0.36 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $70 | $5.69 | +1,130.23% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.65 | +514.16% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.32 | +532.53% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.27 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.49 | +303.28% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $305.52 | -8.35% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.70 | +68.22% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.61 | - | 10 | Jan 19, 2023 |
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.97
Upside: +204.57%
Exelixis
Jun 23, 2025
Maintains: Market Outperform
Price Target: $47 → $50
Current: $43.09
Upside: +16.04%
Elevation Oncology
Jun 10, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.81
Upside: +211.85%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.41
Upside: +148.96%
CRISPR Therapeutics AG
May 21, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $46.70
Upside: +84.15%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $2.65
Upside: +126.42%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $12.35
Upside: +61.94%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.88
Upside: +84.43%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $0.89
Upside: +574.16%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.59
Upside: +401.39%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $4.00
Upside: +400.00%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.31
Upside: +1,197.71%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.36
Upside: -
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $5.69
Upside: +1,130.23%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.65
Upside: +514.16%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.32
Upside: +532.53%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.27
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.49
Upside: +303.28%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $305.52
Upside: -8.35%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.70
Upside: +68.22%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.61
Upside: -